Objectif Silvercatpharma project aims at developing C-C cross-coupling reactions catalysed by d11-blocks metals, particularly silver, for the synthesis of pharmaceuticals in Novartis. It strives to have an impact in terms of cost, environment and international visibility because of the use of silver as an alternative catalyst. The project offers me a great opportunity to obtain further training, such as clusters preparation, computational and flow chemistry, and to define my final career in academia or industry because of the possibility of working in these two different environments. Champ scientifique natural scienceschemical sciencesorganic chemistrymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesbasic medicinemedicinal chemistrynatural scienceschemical sciencesinorganic chemistrytransition metalsnatural scienceschemical sciencescatalysis Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Thème(s) MSCA-IF-2014-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF) Appel à propositions H2020-MSCA-IF-2014 Voir d’autres projets de cet appel Régime de financement MSCA-IF-EF-ST - Standard EF Coordinateur FUNDACIO PRIVADA INSTITUT CATALA D'INVESTIGACIO QUIMICA Contribution nette de l'UE € 158 121,60 Adresse AVENIDA PAISSOS CATALANS 16 43007 Tarragona Espagne Voir sur la carte Région Este Cataluña Tarragona Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 158 121,60
